Dog Senior Pain Management Advances

New pain management options for senior dogs including anti-NGF antibodies, gabapentin, and regenerative therapies are improving quality of life for dogs with chronic musculoskeletal pain.

Key Facts

Osteoarthritis affects an estimated 20-35% of all dogs and over 60% of dogs over 7 years
Bedinvetmab and frunevetmab (anti-NGF monoclonal antibodies) provide monthly injectable pain relief
Gabapentin is increasingly used for chronic neuropathic pain in senior dogs
Physical therapy, hydrotherapy, and acupuncture show evidence of benefit in canine chronic pain management
Many dogs with treated arthritis show dramatic return of activity and apparent wellbeing

Welfare Considerations

Advances in canine pain management are transforming the welfare outcomes of senior dogs with chronic musculoskeletal conditions. Anti-NGF monoclonal antibodies that block pain signaling at the nerve growth factor level provide month-long pain relief from a single injection with minimal side effects — a significant improvement over daily NSAID management. These treatments are enabling dogs previously written off as "just getting old" to regain mobility, activity, and apparent enjoyment of life. The welfare impact of properly treated chronic pain in senior dogs is profound, demonstrating that many dogs accepted as living with reduced quality of life could be significantly better with appropriate treatment.

What You Can Do

Request assessment for anti-NGF therapy for senior dogs with arthritis signs uncontrolled by NSAIDs
Explore physical rehabilitation and hydrotherapy as adjunct treatments for arthritic senior dogs
Implement environmental modifications including ramps and orthopedic beds alongside medical management
Schedule biannual mobility assessments for dogs over 7 to track and treat emerging pain early